Invention Grant
- Patent Title: Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
-
Application No.: US18046291Application Date: 2022-10-13
-
Publication No.: US12157891B2Publication Date: 2024-12-03
- Inventor: Sahar Gelfman , Ann Ligocki , Giovanni Coppola , Aris Baras , Arden Moscati , Eli A. Stahl , Carmelo Romano , Santiago Mendez Huergo , Jonathan Weyne , Tave Van Zyl
- Applicant: Regeneron Pharmaceuticals, Inc.
- Applicant Address: US NY Tarrytown
- Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee Address: US NY Tarrytown
- Agency: Armstrong Teasdale LLP
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61P27/02 ; C12N9/22 ; C12Q1/37
Abstract:
The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.
Public/Granted literature
- US20230250434A1 Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors Public/Granted day:2023-08-10
Information query
IPC分类:
